Cargando…

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Goonewardena, Sascha N., Rosenson, Robert S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the American College of Cardiology Foundation. Published by Elsevier. 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842103/ https://www.ncbi.nlm.nih.gov/pubmed/36653091 http://dx.doi.org/10.1016/j.jacc.2022.11.014

Ejemplares similares

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

Association of Blood Viscosity With Mortality Among Patients Hospitalized With COVID-19
por: Choi, Daein, et al.
Publicado: (2022)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
por: Girona, Josefa, et al.
Publicado: (2016)

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
por: Caselli, Chiara, et al.
Publicado: (2019)

A Genetic Approach to the Association Between PCSK9 and Sepsis
por: Feng, QiPing, et al.
Publicado: (2019)

Efficacy of Statin Therapy in Patients with Hospital Admission for COVID-19
por: Choi, Daein, et al.
Publicado: (2021)

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
por: Rosenson, Robert S., et al.
Publicado: (2016)

PCSK9 Inhibition: Does Lipoprotein Size Matter?
por: Si‐Tayeb, Karim, et al.
Publicado: (2015)

Lipoprotein(a) and PCSK9 inhibition: clinical evidence
por: Ruscica, Massimiliano, et al.
Publicado: (2020)

Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Wang, Yu, et al.
Publicado: (2016)

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
por: Navarese, Eliano P., et al.
Publicado: (2023)

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
por: Fischer, Laurenz T., et al.
Publicado: (2021)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation
por: Kosenko, Tanja, et al.
Publicado: (2013)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
por: Shapiro, Michael D., et al.
Publicado: (2019)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
por: Afanasieva, Olga, et al.
Publicado: (2020)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
por: Andreadou, Ioanna, et al.
Publicado: (2020)

Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance
por: Macchi, C., et al.
Publicado: (2020)

Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
por: Mohamed, Farzahna, et al.
Publicado: (2023)

Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients
por: Goonewardena, Sascha N., et al.
Publicado: (2021)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
por: Rymer, Jennifer A., et al.
Publicado: (2020)

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
por: Johns, Douglas G., et al.
Publicado: (2023)

Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
por: Li, Tingting, et al.
Publicado: (2021)

ASSOCIATION OF BLOOD VISCOSITY AND PROGNOSIS OF HOSPITALIZED COVID-19 PATIENTS
por: Choi, Daein, et al.
Publicado: (2022)

Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans
por: Derington, Catherine G., et al.
Publicado: (2021)

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
por: Chan, Dick C., et al.
Publicado: (2018)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
por: Adorni, Maria Pia, et al.
Publicado: (2017)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Blood hyperviscosity in acute and recent COVID-19 infection
por: Shaik, Aleesha, et al.
Publicado: (2022)

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
por: Peng, Jia, et al.
Publicado: (2020)

ELEVATED BLOOD VISCOSITY PREDICTS A HIGHER MORTALITY AMONG HOSPITALIZED PATIENTS WITH COVID-19
por: Choi, Daein, et al.
Publicado: (2022)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
por: Kohli, Payal, et al.
Publicado: (2016)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
por: Duff, Christopher J., et al.
Publicado: (2009)

Adipocyte Ceramides—The Nexus of Inflammation and Metabolic Disease
por: Chaurasia, Bhagirath, et al.
Publicado: (2020)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy
por: Koren, Michael J., et al.
Publicado: (2015)

Study on Regulation of Low Density Lipoprotein Cholesterol Metabolism using PCSK9 Gene Silencing: A computational Approach
por: Vijayaraghavan, Bhooma, et al.
Publicado: (2018)

New Insights Into the Regulation of Lipoprotein Metabolism by PCSK9: Lessons From Stable Isotope Tracer Studies in Human Subjects
por: Ying, Qidi, et al.
Publicado: (2021)

Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
por: Nava-Salazar, Sonia, et al.
Publicado: (2022)

Association of blood viscosity and device-free days among hospitalized patients with COVID-19
por: Waksman, Ori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m31du62mdd7ch5eougrvusi5he